Roivant Sciences (NASDAQ:ROIV) Announces Earnings Results, Beats Estimates By $0.57 EPS

Roivant Sciences (NASDAQ:ROIV) posted its quarterly earnings data on Wednesday. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.57, FiscalAI reports. Roivant Sciences had a negative return on equity of 19.04% and a negative net margin of 6,079.94%.The firm had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.41 million. During the same quarter in the previous year, the company earned ($0.29) EPS.

Here are the key takeaways from Roivant Sciences’ conference call:

• Roivant reported encouraging preliminary open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, with about 73% ACR20, over 50% ACR50, and more than one-third ACR70 responses in a heavily refractory population.
• The company said the RA data looked especially strong in the JAK- and TNF-refractory subgroup, and management emphasized that the treatment was safe and well-tolerated with no new drug-related safety signals identified.
• Roivant expects to use the RA results, along with additional patient-level analysis, to engage FDA on the future development path for IMVT-1402 later this year, including how many registrational studies may ultimately be needed.
• For mosliciguat in PH-ILD, management highlighted strong Phase I signals, including roughly 30% average PVR reduction and about 38% peak PVR reduction, with good tolerability and limited systemic side effects.
• Roivant said its PH-ILD Phase II study is fully enrolled at 135 patients, the vast majority reached the target dose, and topline data is expected in the second half of 2026; the company also reiterated a strong cash position of $4.3 billion pre-Moderna settlement.

Roivant Sciences Price Performance

ROIV traded down $1.09 during trading on Thursday, reaching $31.32. 1,540,474 shares of the stock traded hands, compared to its average volume of 6,034,281. The stock’s 50-day simple moving average is $28.43 and its two-hundred day simple moving average is $24.95. Roivant Sciences has a fifty-two week low of $10.59 and a fifty-two week high of $32.79. The stock has a market cap of $22.42 billion, a price-to-earnings ratio of -26.78 and a beta of 1.14.

Roivant Sciences News Roundup

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant beat earnings expectations for the quarter, reporting an adjusted EPS of $0.28 versus consensus near a loss, helping drive investor optimism around the company’s improving profitability. Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
• Positive Sentiment: Management pointed to major near-term pipeline and business catalysts, including an anticipated $950 million Moderna-related payment in July and second-half 2026 readouts for mosliciguat and IMVT-1402. Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts
• Positive Sentiment: Investor sentiment was also supported by strength in Roivant affiliate Immunovant, whose trial results were described as clinically meaningful, reinforcing the value of Roivant’s broader biotech pipeline. 2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug
• Neutral Sentiment: The quarter was not uniformly strong, as revenue missed estimates and the company remains unprofitable on a net basis, leaving some questions about the durability of the rally. Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
• Neutral Sentiment: Options activity showed unusually heavy put buying, suggesting some traders were hedging or betting on volatility around the earnings announcement.

Insider Activity at Roivant Sciences

In other news, Director Melissa B. Epperly sold 41,861 shares of Roivant Sciences stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $28.68, for a total transaction of $1,200,573.48. Following the completion of the sale, the director directly owned 15,804 shares in the company, valued at $453,258.72. The trade was a 72.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Frank Torti sold 587,390 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $27.51, for a total value of $16,159,098.90. Following the completion of the sale, the insider directly owned 13,736,547 shares of the company’s stock, valued at approximately $377,892,407.97. The trade was a 4.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 2,345,173 shares of company stock worth $65,251,917. 10.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ROIV. Bank of Montreal Can raised its holdings in shares of Roivant Sciences by 1.3% during the 4th quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock valued at $868,000 after purchasing an additional 516 shares in the last quarter. Allworth Financial LP increased its position in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares during the last quarter. Utah Retirement Systems increased its position in Roivant Sciences by 3.0% during the third quarter. Utah Retirement Systems now owns 20,626 shares of the company’s stock worth $312,000 after buying an additional 600 shares during the last quarter. UMB Bank n.a. raised its holdings in Roivant Sciences by 10.3% during the fourth quarter. UMB Bank n.a. now owns 6,620 shares of the company’s stock valued at $144,000 after buying an additional 620 shares in the last quarter. Finally, M&T Bank Corp lifted its position in shares of Roivant Sciences by 10.2% in the second quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after buying an additional 1,181 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ROIV shares. HC Wainwright reissued a “buy” rating and issued a $34.00 target price on shares of Roivant Sciences in a research report on Thursday. Piper Sandler lifted their price objective on shares of Roivant Sciences from $22.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 16th. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a research note on Thursday. Sanford C. Bernstein assumed coverage on Roivant Sciences in a research report on Friday, March 20th. They issued an “outperform” rating and a $35.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Roivant Sciences in a report on Friday, May 8th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.55.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.